Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Laurence Bozec Le Moal"'
Autor:
Frederic Peyrade, Christophe Le Tourneau, Jérôme Fayette, Joël Guigay, Laura Faivre, J. Delaye, Didier Cupissol, Laurence Digue, Brigitte Laguerre, François Bidault, Christian Borel, Caroline Even, Laurence Bozec Le Moal, Sylvie Zanetta, Frederic Rolland, Anne Auperin, Valérie Costes, Pascal Do
Publikováno v:
Journal of Clinical Oncology. 34:6086-6086
6086Background: SGC of head and neck (SGCHN) are rare tumors including adenoid cystic carcinoma (ACC) and non-ACC, with no standard systemic treatment for R/M patients (pts). Pazopanib (Pb) is an o...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d8ef0a4f1313ffbb39b28ec1ae0197e4
https://doi.org/10.1200/jco.2016.34.15_suppl.6086
https://doi.org/10.1200/jco.2016.34.15_suppl.6086
Autor:
Yoann Pointreau, Jérôme Fayette, Lydia Brugel Ribere, Isabelle Tennevet, Anne-Françoise Dillies, Sylvie Zanetta, Joseph Kerger, Laurence Bozec Le Moal, Christian Sire, Stefanie Henry, Jean-Pascal Machiels, Stéphane Temam, Gortec, Joël Guigay
Publikováno v:
Journal of Clinical Oncology. 30:5505-5505
5505 Background: Cetuximab in combination with platinum and 5FU (PFEx) has become a standard in first-line treatment of patients (pts) with R/M SCCHN. Cetuximab and taxane combinations have shown promising activity. This multicenter phase II study ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fdd21ecfb53907ce4dde1e7190b415bd
https://doi.org/10.1200/jco.2012.30.15_suppl.5505
https://doi.org/10.1200/jco.2012.30.15_suppl.5505